Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: A post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies

Journal of Clinical Psychiatry

Volumn 69, Issue 5, 2008, Pages 769-782

  Weisler, Richard H ^a,b   Calabrese, Joseph R ^c   Thase, Michael E ^d   Arvekvist, Robert ^e   Stening, Göran ^e   Paulsson, Björn ^e   Suppes, Trisha ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE; ZOLPIDEM;

ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EFFECT SIZE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; HYPERACTIVITY; HYPOMANIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREMOR; XEROSTOMIA;

EID: 45249124941     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0510     Document Type: Article

References (58)

1. Keck PE Jr, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry 2003;53:671-679
2. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445-457
3. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
4. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003 Jun;64(6):680-690
5. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002 Sep;63(9):807-811
6. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269
7. Gladstone GL, Mitchell PB, Parker G, et al. Indicators of suicide over 10 years in a specialist mood disorders unit sample. J Clin Psychiatry 2001 Dec;62(12):945-951
8. Lopez P, Mosquera F, de Leon J, et al. Suicide attempts in bipolar patients. J Clin Psychiatry 2001 Dec;62(12):963-966
9. Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry 2001;62(suppl 25):27-30
10. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr 2006;11:465-471
11. Hiroeh U, Appleby L, Mortensen PB, et al. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001;358:2110-2112
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder (revision). Am J Psychiatry 2002 Apr;159(suppl 4):1-50
13. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005 Jul;66(7):870-886
14. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999 Feb;60(2):79-88
15. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614
16. Sachs G, Altshuler L, Ketter T. Divalproex versus placebo for the treatment of bipolar depression. Paper presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii
17. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
18. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
19. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-266
20. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609
21. Weisler RH, Cutler AJ, Ballenger JC, et al. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr 2006;11:788-799
22. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-bind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-333
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
24. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006 Jul;67(7):1025-1033
25. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435
26. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
27. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001 Sep;62(9):728-732
28. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002 Dec;63(12):1156-1163
29. Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2007 May 11:1-14 [Epub ahead of print]
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
34. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
35. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
36. Sheehan DV. The Anxiety Disease. New York, NY: Scribner's; 1983
37. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
38. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
39. Bowden CL, Davis J, Morris D, et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997;6:26-30
40. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, pt 1: treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-124
41. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-739
42. Fountoulakis KN, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007 Oct;6:27
43. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA 2003;290:1517-1519
44. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996;39:896-899
45. Goodwin F, Jamison K. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
46. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997;170:205-228
47. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999;60(suppl 2):53-56, discussion 75-76, 113-116
48. Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003;5:58-61
49. US Food and Drug Administration. FDA Alert. Suicidality and antiepileptic drugs. Jan 31, 2008. Available at: http://www.fda.gov/cder/drug/infopage/ antiepileptics. Updated Feb 1, 2008. Accessed Feb 25, 2008
50. Grunze H. Reevaluating therapies for bipolar depression. J Clin Psychiatry 2005;66(suppl 5):17-25
51. Mallinckrodt CH, Clark SW, Carroll RJ, et al. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-190
52. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004 Sep;4:26
53. Hirschfeld RM, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Mar;67(3):355-362
54. Baptista T, Kin NM, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-219
55. Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003 Sep;64(9):1101-1105
56. Trivedi MH, Greer TL, Grannemann BD, et al. Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract 2006;12:205-213
57. Masand PS, Culpepper L, Henderson D, et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005 Oct;10(suppl 14):1-15
58. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601